Subscribe To
Gbpusd weekly analysis – june 4, 2023
The GBPUSD currency pair has entered a phase of consolidation following the previous uptrend from 1.035...
June 4, 2023, 3:36 am
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal s
– Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the phase ...
June 3, 2023, 8:00 pm
Cogent biosciences announces positive lead-in data from ongoing phase 3 peak trial evaluating bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors (gist)
– Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% ...
June 3, 2023, 6:15 pm
Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker r...
June 3, 2023, 1:00 pm
Allogene therapeutics presents updated allo-501/501a phase 1 data in large b cell lymphoma at the american society of clinical oncology (asco) annual meeting
Long Term Follow Up Data from phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR ...
June 3, 2023, 1:00 pm
Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker r...
June 3, 2023, 1:00 pm
Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker r...
June 3, 2023, 1:00 pm
Elicio therapeutics announces positive interim data from the phase 1 study of an investigational therapeutic cancer immunotherapy, eli-002, in patients with high relapse risk pancreatic and colorectal
ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker r...
June 3, 2023, 1:00 pm